表紙
市場調查報告書

特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析

Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035

出版商 Datamonitor Healthcare 商品編碼 365208
出版日期 內容資訊 英文 171 Pages
商品交期: 最快1-2個工作天內
價格
特發性肺纖維化 (IPF):流行病學、病患人數的市場預測、治療流程、上市藥及開發平台藥物分析 Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035
出版日期: 2018年08月07日內容資訊: 英文 171 Pages
簡介

2014年10月,FDA同時承認了Esbriet及Ofev作為美國第一個特發性肺纖維化 (IPF) 治療藥。

本報告提供特發性肺纖維化 (IPF) 治療藥趨勢調查,市場定義和概要,疾病定義與診斷,目前治療選擇,處方趨勢,已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:特發性肺纖維化 (IPF)

  • 摘要整理
  • 市場概要、趨勢
  • 調查手法、市場定義
  • Esbriet (pirfenidone)
  • Ofev (nintedanib)
  • 一次調查技術

治療方法:特發性肺纖維化 (IPF)

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢

流行病學:美國、日本、歐盟5國的特發性肺纖維化 (IPF)

  • 摘要整理
  • 資訊來源、分析方法
  • 預測
  • 流行病學者的見解
  • 優勢、規定

上市藥:特發性肺纖維化 (IPF)

  • 摘要整理
  • 產品概要
  • 產品簡介:Esbriet
  • 產品簡介:Ofev

開發平台:特發性肺纖維化 (IPF)

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶治療藥簡介
  • 臨床試驗設計
  • 產品簡介 (開發後期):FG-3019
  • 產品簡介 (開發後期):PRM-151
目錄
Product Code: DMKC12770

Overview

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. While lung function and capacity steadily decline in most IPF patients, some experience a sudden, rapid increase in irreversible disease progression called acute exacerbation. The prognosis of patients with IPF remains poor as those who are ineligible for lung transplantation have few effective treatment options.

Market Snapshot

  • Ofev will succeed Esbriet as market leader following the release of favorable real-world evidence.
  • Treatment of IPF is evolving as mounting evidence and revised international guidelines support clinical decision-making.
  • IPF is a complex and fatal disease with most cases in older populations aged ≥50 years.
  • Ofev is overtaking Esbriet, as new real-world evidence suggests that its clinical profile in pivotal trials was understated.
  • Pipeline therapies producing proven risk reductions in all-cause mortality will command a price premium.

TABLE OF CONTENTS

FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ESBRIET
  • PRODUCT PROFILE: OFEV

TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 07 August 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ESBRIET
  • PRODUCT PROFILE: OFEV

PIPELINE: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): GLPG1690
  • PRODUCT PROFILE (LATE STAGE): PBI-4050
  • PRODUCT PROFILE (LATE STAGE): PRM-151
  • PRODUCT PROFILE (LATE STAGE): PAMREVLUMAB

LIST OF FIGURES

  • Figure 1: Idiopathic pulmonary fibrosis - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for idiopathic pulmonary fibrosis
  • Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Idiopathic pulmonary fibrosis drug sales in the US, 2016-25
  • Figure 5: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016-25
  • Figure 6: Patient-based forecast methodology for idiopathic pulmonary fibrosis
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Esbriet for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 11: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Ofev for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Ofev for idiopathic pulmonary fibrosis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Ofev for idiopathic pulmonary fibrosis
  • Figure 15: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Distribution of diagnosed idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by severity and country (%)
  • Figure 17: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
  • Figure 18: Estimated percentage of IPF patients who experience acute exacerbation in the US, Japan, and five major EU markets, by severity and country
  • Figure 19: Overview of the ATS/ERS/JRS/ALAT evidence-based guidelines for the treatment of idiopathic pulmonary fibrosis
  • Figure 20: Percentage of IPF patients who fall into each treatment category in the US, Japan, and five major EU markets, by severity and country
  • Figure 21: Top five pharmacological treatment regimens used in mild IPF patients across the US, Japan, and five major EU markets, by country
  • Figure 22: Top five pharmacological treatment regimens used in moderate IPF patients across the US, Japan, and five major EU markets, by country
  • Figure 23: Top five pharmacological treatment regimens used in severe IPF patients across the US, Japan, and five major EU markets, by country
  • Figure 24: Use of Esbriet and Ofev, whether alone or in a combination, across the US, Japan, and five major EU markets, by severity and country
  • Figure 25: Percentage use of Esbriet and Ofev as monotherapy and in each combination across the US, Japan, and five major EU markets, by severity
  • Figure 26: Patients who receive supplemental anti-gastroesophageal reflux medications across the US, Japan, and five major EU markets, by severity and country (%)
  • Figure 27: Non-pharmacological treatments used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 28: Non-pharmacological treatments used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 29: Non-pharmacological treatments used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Figure 30: Trends in diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 31: Trends in diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 32: Esbriet for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
  • Figure 35: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 36: Ofev for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Ofev for idiopathic pulmonary fibrosis
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Ofev for idiopathic pulmonary fibrosis
  • Figure 39: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 40: GLPG1690 for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
  • Figure 42: Datamonitor Healthcare's drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
  • Figure 43: PBI-4050 for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 44: Datamonitor Healthcare's drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
  • Figure 46: PRM-151 for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 47: Datamonitor Healthcare's drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
  • Figure 48: Datamonitor Healthcare's drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
  • Figure 49: Pamrevlumab for idiopathic pulmonary fibrosis - SWOT analysis
  • Figure 50: Datamonitor Healthcare's drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis

LIST OF TABLES

  • Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare's idiopathic pulmonary fibrosis patientbased forecast
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
  • Table 4: Esbriet drug profile
  • Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
  • Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 7: Ofev drug profile
  • Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
  • Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
  • Table 11: Subtypes of idiopathic interstitial pneumonias
  • Table 12: Datamonitor Healthcare's definition of idiopathic pulmonary fibrosis severity
  • Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
  • Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
  • Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Table 18: Pharmacological treatment regimens used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Table 19: Pharmacological treatment regimens used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
  • Table 20: Sources used for the epidemiological analysis of IPF in the US, Japan, and five major EU markets, by country
  • Table 21: Diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 22: Diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 23: Profiled key marketed drugs for idiopathic pulmonary fibrosis
  • Table 24: Esbriet drug profile
  • Table 25: Esbriet Phase III data in idiopathic pulmonary fibrosis
  • Table 26: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 27: Ofev drug profile
  • Table 28: Ofev pivotal trial data in idiopathic pulmonary fibrosis
  • Table 29: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 30: Phase II pipeline products in development for idiopathic pulmonary fibrosis
  • Table 31: GLPG1690 drug profile
  • Table 32: GLPG1690 Phase II data in idiopathic pulmonary fibrosis
  • Table 33: PBI-4050 drug profile
  • Table 34: PBI-4050 Phase II data in idiopathic pulmonary fibrosis
  • Table 35: PRM-151 drug profile
  • Table 36: PRM-151 Phase II trial in idiopathic pulmonary fibrosis
  • Table 37: PRM-151 Phase I data in idiopathic pulmonary fibrosis
  • Table 38: Pamrevlumab drug profile
  • Table 39: Pamrevlumab Phase II data in idiopathic pulmonary fibrosis